GSK and development partner Ionis announced positive topline results from two pivotal Phase 3 trials of bepirovirsen, an antisense oligonucleotide aimed at inducing functional cure in chronic hepatitis B. The companies said the studies met primary endpoints and that global regulatory filings are planned. The announcement represents an important step toward a finite treatment for CHB, moving beyond life-long viral suppression. The trials enrolled more than 1,800 patients across multiple countries. GSK and Ionis did not disclose full data with the initial releases but signaled that the therapy achieved clinically meaningful functional-cure rates at six months. The firms will publish detailed results and outline regulatory submission timing as part of the next development phase.